TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07797231: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial With an Open-Label Extension to Evaluate the Efficacy and Safety of TQA3605 Tablets in Chronic Hepatitis B Virus-Infected Patients With Low-Level Viremia or

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 930 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,600,088

Rescue Site Savings

+$5,677,728

Unlock Full NCT07797231 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07797231 Rescue Dossier →